These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 17466419

  • 21. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T.
    Vaccine; 2015 Sep 22; 33(39):5217-24. PubMed ID: 26232542
    [Abstract] [Full Text] [Related]

  • 22. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G, Naess LM, Acevedo R, Fjeldheim ÅK, Bolstad K, García L, Cardoso D, Aase A, Zayas C, González H, Rosenqvist E, Norheim G.
    Vaccine; 2014 Nov 20; 32(49):6631-8. PubMed ID: 25305564
    [Abstract] [Full Text] [Related]

  • 23. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G, Aase A, Caugant DA, Høiby EA, Fritzsønn E, Tangen T, Kristiansen P, Heggelund U, Rosenqvist E.
    Vaccine; 2005 May 31; 23(29):3762-74. PubMed ID: 15893613
    [Abstract] [Full Text] [Related]

  • 24. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.
    Hou VC, Koeberling O, Welsch JA, Granoff DM.
    J Infect Dis; 2005 Aug 15; 192(4):580-90. PubMed ID: 16028126
    [Abstract] [Full Text] [Related]

  • 25. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
    Wyplosz B, Derradji O, Hong E, François H, Durrbach A, Duclos-Vallée JC, Samuel D, Escaut L, Launay O, Vittecoq D, Taha MK.
    Transpl Infect Dis; 2015 Apr 15; 17(2):322-7. PubMed ID: 25645691
    [Abstract] [Full Text] [Related]

  • 26. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.
    Vaccine; 2015 May 15; 33(21):2500-10. PubMed ID: 25795256
    [Abstract] [Full Text] [Related]

  • 27. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.
    Li Y, Zhang Q, Winterbotham M, Mowe E, Gorringe A, Tang CM.
    Infect Immun; 2006 Nov 15; 74(11):6348-55. PubMed ID: 16966413
    [Abstract] [Full Text] [Related]

  • 28. Authors' response: Meningococcal vaccine antigen diversity in global databases.
    Brehony C, Hill DM, Lucidarme J, Borrow R, Maiden MC.
    Euro Surveill; 2016 Apr 14; 21(15):. PubMed ID: 27104935
    [No Abstract] [Full Text] [Related]

  • 29. Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant.
    Haneberg B, Dalseg R, Oftung F, Wedege E, Høiby EA, Haugen IL, Holst J, Andersen SR, Aase A, Meyer Naess L, Michaelsen TE, Namork E, Haaheim LR.
    Dev Biol Stand; 1998 Apr 14; 92():127-33. PubMed ID: 9554266
    [Abstract] [Full Text] [Related]

  • 30. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E.
    Vaccine; 2009 Jun 24; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.
    Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G.
    Infect Immun; 2005 Oct 24; 73(10):6838-45. PubMed ID: 16177362
    [Abstract] [Full Text] [Related]

  • 32. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.
    Verheul AF, Van Gaans JA, Wiertz EJ, Snippe H, Verhoef J, Poolman JT.
    Infect Immun; 1993 Jan 24; 61(1):187-96. PubMed ID: 8418041
    [Abstract] [Full Text] [Related]

  • 33. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.
    de Jonge MI, Hamstra HJ, Jiskoot W, Roholl P, Williams NA, Dankert J, van Alphen L, van der Ley P.
    Vaccine; 2004 Sep 28; 22(29-30):4021-8. PubMed ID: 15364452
    [Abstract] [Full Text] [Related]

  • 34. Intranasal and Intramuscular Immunization with Outer Membrane Vesicles from Serogroup C Meningococci Induced Functional Antibodies and Immunologic Memory.
    Izeli Portilho A, Araujo Correa V, Dos Santos Cirqueira C, De Gaspari E.
    Immunol Invest; 2022 Oct 28; 51(7):2066-2085. PubMed ID: 35950702
    [Abstract] [Full Text] [Related]

  • 35. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M.
    N Z Med J; 2004 Aug 20; 117(1200):U1016. PubMed ID: 15475986
    [Abstract] [Full Text] [Related]

  • 36. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M, Fantoni S.
    Minerva Med; 2007 Oct 20; 98(5):575-89. PubMed ID: 18043565
    [Abstract] [Full Text] [Related]

  • 37. Meningococcal surrogates of protection--serum bactericidal antibody activity.
    Borrow R, Balmer P, Miller E.
    Vaccine; 2005 Mar 18; 23(17-18):2222-7. PubMed ID: 15755600
    [Abstract] [Full Text] [Related]

  • 38. Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis.
    Steeghs L, Keestra AM, van Mourik A, Uronen-Hansson H, van der Ley P, Callard R, Klein N, van Putten JP.
    Infect Immun; 2008 Aug 18; 76(8):3801-7. PubMed ID: 18490457
    [Abstract] [Full Text] [Related]

  • 39. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL, van den Dobbelsteen GP, de Groot R.
    Curr Opin Mol Ther; 2003 Feb 18; 5(1):33-8. PubMed ID: 12669468
    [Abstract] [Full Text] [Related]

  • 40. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R, Beernink PT, Giuntini S, Granoff DM.
    Clin Vaccine Immunol; 2015 Dec 18; 22(12):1227-34. PubMed ID: 26424832
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.